Wednesday, 16 April 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 16 April 2025
News

Local eye drug falls at final hurdle

Posted 27 March 2025 PM

Melbourne-based biotech Opthea has announced catastrophic news, with the Phase 3 failure of its eye drug raising the possibility the company could be made to repay money invested in it and go under.

The global COAST Phase 3 trial of VEGF-C and VEGF-D inhibitor OPT-302, or sozinibercept, with 2mg administered intravitreally every four or eight weeks in combination with 2mg of Bayer's Eylea every eight weeks failed to meet its primary endpoint.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (13)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (6)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.